Samalin Investment Counsel LLC Makes New $59,000 Investment in Precision BioSciences, Inc. (NASDAQ:DTIL)

Samalin Investment Counsel LLC bought a new position in Precision BioSciences, Inc. (NASDAQ:DTIL) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 15,545 shares of the company’s stock, valued at approximately $59,000.

Several other hedge funds have also recently made changes to their positions in DTIL. Janus Henderson Group PLC raised its holdings in shares of Precision BioSciences by 10.9% during the third quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock valued at $6,322,000 after purchasing an additional 68,943 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Precision BioSciences by 40.7% during the third quarter. Geode Capital Management LLC now owns 65,974 shares of the company’s stock valued at $591,000 after purchasing an additional 19,088 shares during the last quarter. Moloney Securities Asset Management LLC raised its holdings in shares of Precision BioSciences by 177.0% during the fourth quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock valued at $335,000 after purchasing an additional 56,100 shares during the last quarter. Finally, Commonwealth Equity Services LLC purchased a new position in shares of Precision BioSciences during the fourth quarter valued at approximately $48,000. 37.99% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DTIL has been the subject of several research reports. BMO Capital Markets raised shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective for the company in a report on Friday, January 10th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Precision BioSciences in a report on Wednesday, March 19th.

Insider Activity at Precision BioSciences

In related news, insider J. Jefferson Smith sold 10,287 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $4.79, for a total transaction of $49,274.73. Following the completion of the sale, the insider now directly owns 87,440 shares in the company, valued at approximately $418,837.60. The trade was a 10.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael Amoroso sold 36,838 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total transaction of $172,033.46. Following the sale, the chief executive officer now owns 107,087 shares of the company’s stock, valued at $500,096.29. This trade represents a 25.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders acquired 8,734 shares of company stock worth $39,946 and sold 47,279 shares worth $222,064. 4.00% of the stock is currently owned by company insiders.

Precision BioSciences Stock Performance

Shares of NASDAQ DTIL opened at $5.45 on Monday. The firm has a 50 day moving average of $5.14 and a 200 day moving average of $6.68. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $41.81 million, a price-to-earnings ratio of 90.85 and a beta of 1.59. Precision BioSciences, Inc. has a 12-month low of $3.61 and a 12-month high of $15.97.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.